



APPLIED PHARMA RESEARCH S.A.

APR Applied Pharma Research s.a. opens US office in Charlotte, North Carolina

September 5th, 2007

Balerna (Switzerland). APR Applied Pharma Research s.a. ("APR") a leading international Drug Research & Development company, is pleased to announce the opening of the Applied Pharma Research USA, LLC office in Charlotte, North Carolina in the United States. The new office will be responsible for APR's operations in the North and South America regions.

"The opening of our office in Charlotte reflects the increasing interest and demand for our patented drug delivery systems and innovative products in these markets" says Paolo Galfetti, CEO of APR. "The decision to establish an office in the United States is consistent with our international growth plans and the desire to better support our partners in the region"

The APR USA office and operations will be managed by Aldo Donati, who joins the group after a period of external cooperation with APR. Mr. Donati will be responsible for all Business Development & Licensing activities of APR in the region. Mr. Donati brings to APR USA extensive international business development and management experience having established and managed licensing partnerships and operations in several markets including the United States, Western and Eastern Europe, Latin America and the Caribbean Region. "APR is in the final stages of development of an ondansetron and a donepezil formulation using its proprietary RapidFilm© oral thin film technology and of a diclofenac sodium Matrix© transdermal patch" says Aldo Donati "We are extremely pleased with the level of interest shown in the North American markets for these formulations and the patented technologies developed by APR. The opening of the Charlotte office will allow us to more effectively present our products in these markets"

About APR Applied Pharma Research s.a.

APR Applied Pharma Research s.a. is a privately owned internationally oriented Drug Research & Development company headquartered in Switzerland. The privately held company, focuses its efforts on the development of its own selected drug candidates (developed using APR proprietary technologies) as well as on the development under contract of third party pharmaceutical products and medical devices. Leveraging on its own technology platforms, R&D know-how and marketing and regulatory systems, APR is committed to create new sustainable value on its own as well as on third party products and projects.

The APR products and technologies are licensed to third parties for distribution and marketing. R&D activities are carried out directly or under contract. APR has signed licensing agreements with pharmaceutical companies in about 35 countries worldwide and its sales are almost totally achieved abroad.

Contacts:

Paolo Galfetti; CEO APR Applied Pharma Research s.a., www.apr.ch - Via Corti 5, CH - 6828 Balerna, Switzerland Tel: +41 91 6957020 - paolo.galfetti@apr.ch

Aldo Donati; Vice President APR Applied Pharma Research USA, LLC 6129 Wakehurst Rd. - 28226 Charlotte, NC Tel.: (704) 641-1586 Fax (704) 644-3795 - aldo.donati@apr.ch